Option Care Health Boosts Share Buyback Program to $1 Billion, Provides Strong 2026 Guidance
Summary
Option Care Health announced a significant expansion of its share repurchase program to $1 billion, alongside preliminary Q4 and full-year 2025 results and optimistic financial guidance for 2026.
Key Events
-
Share Repurchase Program Expanded
The Board of Directors approved increasing the 2025 share repurchase authorization from $500 million to $1 billion, adding an additional $500 million in capacity. The total remaining capacity is now $693 million.
-
Preliminary 2025 Financial Results
The company reported preliminary full-year 2025 net revenue of $5.645 billion to $5.655 billion and Adjusted EBITDA of $469 million to $473 million.
-
Positive 2026 Financial Guidance
Option Care Health issued preliminary full-year 2026 guidance projecting net revenue of $5.8 billion to $6.0 billion and Adjusted EBITDA of $480 million to $505 million, indicating continued growth despite headwinds.
-
J.P. Morgan Healthcare Conference Presentation
The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with presentation materials furnished as an exhibit.
Analysis
The substantial increase in Option Care Health's share repurchase authorization to $1 billion, representing a significant portion of its market capitalization, is a strong positive signal of management's confidence in future performance and commitment to returning capital to shareholders. This capital allocation strategy, combined with preliminary 2025 results and optimistic 2026 guidance, suggests a robust financial outlook. While the 2026 guidance includes a headwind from Stelara biosimilars, the projected growth in revenue and Adjusted EBITDA indicates underlying business strength. Investors should view the expanded buyback as a material driver for shareholder value.
At the time of this filing, OPCH was trading at $32.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $23.68 to $35.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.